FDA Finalizes New Definition of Biological Product

Patterson Belknap Webb & Tyler LLP

Patterson Belknap Webb & Tyler LLP

Last week, the U.S. Food and Drug Administration (“FDA”) issued a final rule to amend its regulation that defines the term “biological product” in line with the definition set by the Biologics Price Competition and Innovation Act of 2009 (“BPCIA”), as amended by the Further Consolidated Appropriations Act, 2020, enacted on December 20, 2019 (“FCA Act”). 

The BPCIA initially amended the definition of “biological product” in § 351(i) of the Public Health Service Act (“PHS Act”) to include a “protein,” but with a parenthetical carve-out excluding “any chemically synthesized polypeptide.”  The FCA Act later struck this carve-out such that chemically synthesized polypeptides were no longer excluded from the statutory category of “protein.”  The FDA’s final rule makes clear that the agency interprets the term “protein” in line with the latest statutory definition to mean “any alpha amino acid polymer with a specific defined sequence that is greater than 40 amino acids in size,” regardless of whether it is chemically synthesized.

The rule sets the groundwork for the upcoming expiration of the BPCIA’s 10-year transition period on March 23, 2020, after which all therapeutic products meeting the statutory definition of “biological products” will be governed by the PHS Act.  Although the majority of biological products already have been licensed under the PHS Act, some protein products (e.g., insulin and insulin analogs, human growth hormone, pancreatic enzymes, reproductive hormones) historically had been approved under § 505 of the Federal Food, Drug and Cosmetic Act (“FDC Act”). 

The practical effect of the regulation is two-fold.  First, starting on March 23, 2020, insulin products and other biological products approved in the past under § 505 of the FDC Act will now be “deemed” to be licensed and regulated under § 351 of the PHS Act.  Once this transition occurs, sponsors will be able to seek approval of products that are biosimilar to, or interchangeable with, these transitioned products. 

Second, sponsors seeking approval of future biological products that once could have been submitted under § 505 of the FDC Act must now submit a biologics license application under § 351 of the PHS Act.

According to the FDA, the final rule “clarifies the criteria for whether certain products will be regulated as drugs or biological products. The ‘bright-line’ approach under the rule will reduce the amount of time spent by FDA staff and industry in support of making such determinations.”

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Patterson Belknap Webb & Tyler LLP | Attorney Advertising

Written by:

Patterson Belknap Webb & Tyler LLP

Patterson Belknap Webb & Tyler LLP on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.